Shattuck Labs’ (STTK) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright restated their neutral rating on shares of Shattuck Labs (NASDAQ:STTK) in a report released on Friday,Benzinga reports. HC Wainwright also issued estimates for Shattuck Labs’ Q4 2024 earnings at ($0.46) EPS, FY2024 earnings at ($1.54) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($1.03) EPS.

A number of other brokerages also recently issued reports on STTK. Evercore ISI upgraded Shattuck Labs to a “strong-buy” rating in a report on Wednesday, October 2nd. Citigroup cut shares of Shattuck Labs from a “buy” rating to a “neutral” rating and lowered their price target for the company from $8.00 to $2.00 in a report on Wednesday, October 2nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Shattuck Labs in a research note on Thursday, November 14th. Four investment analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.67.

Shattuck Labs Stock Performance

Shares of STTK opened at $1.11 on Friday. The company has a 50 day moving average price of $2.03 and a 200-day moving average price of $4.12. Shattuck Labs has a fifty-two week low of $1.07 and a fifty-two week high of $11.76. The stock has a market capitalization of $52.74 million, a PE ratio of -0.72 and a beta of 1.85.

Insider Buying and Selling

In other news, CEO Taylor Schreiber bought 36,500 shares of Shattuck Labs stock in a transaction that occurred on Monday, October 7th. The stock was bought at an average price of $1.21 per share, for a total transaction of $44,165.00. Following the purchase, the chief executive officer now directly owns 71,002 shares of the company’s stock, valued at approximately $85,912.42. The trade was a 105.79 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 10.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. SG Americas Securities LLC increased its holdings in Shattuck Labs by 4.8% in the 1st quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock worth $352,000 after buying an additional 1,788 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Shattuck Labs by 8.5% in the second quarter. Dimensional Fund Advisors LP now owns 69,062 shares of the company’s stock worth $266,000 after acquiring an additional 5,397 shares during the period. Geode Capital Management LLC raised its holdings in shares of Shattuck Labs by 0.9% during the third quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock worth $3,184,000 after purchasing an additional 8,133 shares during the last quarter. American Century Companies Inc. lifted its position in Shattuck Labs by 25.4% during the second quarter. American Century Companies Inc. now owns 47,367 shares of the company’s stock valued at $183,000 after purchasing an additional 9,608 shares during the period. Finally, Atom Investors LP purchased a new stake in Shattuck Labs in the third quarter valued at $35,000. 58.74% of the stock is owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.